• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Biosimilar to infliximab shows equivalent safety and efficacy for treating Crohn’s disease

byCaitlyn HuiandDeepti Shroff Karhade
December 10, 2018
in Chronic Disease, Gastroenterology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. The biosimilar to infliximab, CT-P13 was shown in this study to have equivalent efficacy to the anti tumor-necrosis factor (TNF) monoclonal antibody for Crohn’s treatment.

2. There was no significant safety differences observed in this study between the two treatments for Crohn’s disease.

Evidence Rating Level: 2 (Good)

Study Rundown: Crohn’s disease is managed by a variety of different treatment options, including the anti-TNF monoclonal antibody known as infliximab. The authors of this study investigated the effectiveness and safety of a new treatment option, CT-P13, which is a biosimilar of the reference product infliximab. A similar safety and efficacy was observed in the biosimilar to infliximab for the treatment of Crohn’s disease. The main limitation of this study was that the authors used proxies to estimate disease severity, since the database utilized in the cohort study did not include all the relevant clinical data necessary for certain clinical indices of Crohn’s. Overall, the study results suggested that the biosimilar CT-P13 is comparable to infliximab.

Click to read the study in Annals of Internal Medicine

Relevant Reading: Role of biologics and biosimilars in inflammatory bowel disease: current trends and future perspectives

In-Depth [comparative equivalence cohort study]: The authors of this study conducted a comparative equivalence cohort study to compare the biosimliar CT-P13 to infliximab, an anti-TNF monoclonal antibody, with regards to safety and efficacy of managing Crohn’s disease. The sample size was calculated with an expected event rate of 40% in each treatment group – patients naïve to infliximab treated with the biosimilar versus infliximab. The main endpoints were composite end point of death, Crohn’s-disease related surgery, all-cause hospitalization and reimbursement of another biologic therapy. There were no safety differences in outcomes observed between the two groups, including differences in serious infections (HR, 0.82 [CI, 0.61 to 1.11]) and tuberculosis (HR, 1.10 [CI, 0.36 to 3.34]). Furthermore,  CT-P13 was found to be equivalent to infliximab in a multivariate analysis (HR, 0.92 [95% CI, 0.85-0.99]) of the primary outcome.

RELATED REPORTS

Anti-TNF for inflammatory bowel disease after 24 weeks of pregnancy does not affect neonatal outcomes

Individuals with autoimmune diseases may have an increased risk for cardiovascular diseases

MRI offers an alternative to endoscopic assessment of disease activity and severity in ileocolonic Crohn’s disease [Classics Series]

Image: PD

©2018 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: biosimilarCPCrohn's DiseaseInfliximab
Previous Post

Quick Take: Analgesic efficacy and safety of morphine in the Procedural Pain in Premature Infants (Poppi) study: randomised placebo-controlled trial

Next Post

Study finds that pediatric residents rarely perform neonatal intubation

RelatedReports

Women electing abortion more likely to be victims of domestic violence
Chronic Disease

Anti-TNF for inflammatory bowel disease after 24 weeks of pregnancy does not affect neonatal outcomes

October 10, 2022
Long-term outcomes for off-pump and on-pump CABG are similar
Cardiology

Individuals with autoimmune diseases may have an increased risk for cardiovascular diseases

September 14, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Radiology Classics

MRI offers an alternative to endoscopic assessment of disease activity and severity in ileocolonic Crohn’s disease [Classics Series]

August 11, 2022
Thalidomide may be effective in refractory pediatric Crohn’s disease
Chronic Disease

Ustekinumab and adalimumab comparable in safety and efficacy for treatment of Crohn’s disease

June 21, 2022
Next Post
AAP addresses neonatal pain prevention

Study finds that pediatric residents rarely perform neonatal intubation

Corticosteroids improve outcomes in treatment of community-acquired pneumonia

Veteran Health hospitals consistently outperform non-Veteran Health hospitals in several measures of quality of care

Engineered stem cells mitigate liver damage caused by radiation [PreClinical]

2 Minute Medicine Rewind December 11, 2018

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Cystatin C-based equation without race or sex improves accuracy of GFR estimation
  • #VisualAbstract: Aldosterone synthase inhibition reduced systolic blood pressure in patients with treatment-resistant hypertension
  • High-dose exercise therapy is not superior to low-dose exercise therapy for knee osteoarthritis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options